source
- RA Capital launches rare disease company Oak Hill Bio onto Nasdaq via SPACRare disease biotech Oak Hill is headed to the Nasdaq through a SPAC merger with RA Capital-sponsored Research Alliance Corporation III (RACC) to fund a rare genetic disease candidate.
- STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain diseaseOak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.